What Could These Clinical Results Mean for AbbVie's Shareholders?

Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. But what impact could these clinical results have on pharma stock AbbVie in the years ahead?

Let's dive into the data studying Rinvoq's effect on patients with ankylosing spondylitis, as well as Rinvoq's U.S. sales potential to address this question.

Image source: Getty Images.

Continue reading

Source Fool.com